These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 18285836

  • 1. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
    Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD.
    Eur J Hum Genet; 2008 Jul; 16(7):820-32. PubMed ID: 18285836
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets.
    Drikos I, Nounesis G, Vorgias CE.
    Proteins; 2009 Nov 01; 77(2):464-76. PubMed ID: 19452558
    [Abstract] [Full Text] [Related]

  • 10. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.
    Williams RS, Lee MS, Hau DD, Glover JN.
    Nat Struct Mol Biol; 2004 Jun 01; 11(6):519-25. PubMed ID: 15133503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BRCT repeats as phosphopeptide-binding modules involved in protein targeting.
    Manke IA, Lowery DM, Nguyen A, Yaffe MB.
    Science; 2003 Oct 24; 302(5645):636-9. PubMed ID: 14576432
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation.
    Fernandes VC, Golubeva VA, Di Pietro G, Shields C, Amankwah K, Nepomuceno TC, de Gregoriis G, Abreu RBV, Harro C, Gomes TT, Silva RF, Suarez-Kurtz G, Couch FJ, Iversen ES, Monteiro ANA, Carvalho MA.
    J Biol Chem; 2019 Apr 12; 294(15):5980-5992. PubMed ID: 30765603
    [Abstract] [Full Text] [Related]

  • 16. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.
    Coquelle N, Green R, Glover JN.
    Biochemistry; 2011 May 31; 50(21):4579-89. PubMed ID: 21473589
    [Abstract] [Full Text] [Related]

  • 17. BRCA1-BRCT Mutations Alter the Subcellular Localization of BRCA1 In Vitro.
    Drikos I, Boutou E, Kastritis PL, Vorgias CE.
    Anticancer Res; 2021 Jun 31; 41(6):2953-2962. PubMed ID: 34083286
    [Abstract] [Full Text] [Related]

  • 18. Detection of a novel mutation in exon 20 of the BRCA1 gene.
    Chakraborty A, Katarkar A, Chaudhuri K, Mukhopadhyay A, Basak J.
    Cell Mol Biol Lett; 2013 Dec 31; 18(4):631-8. PubMed ID: 24297685
    [Abstract] [Full Text] [Related]

  • 19. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K, Koyasu M, Nomura S, Sato Y, Kita M, Ashihara Y, Adachi Y, Ohno S, Iwase T, Kitagawa D, Nakashima E, Yoshida R, Miki Y, Arai M.
    Cancer Sci; 2017 Nov 31; 108(11):2287-2294. PubMed ID: 28796317
    [Abstract] [Full Text] [Related]

  • 20. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination.
    Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, Valerie N, Xu B, Povirk LF, Valerie K.
    Aging (Albany NY); 2011 May 31; 3(5):515-32. PubMed ID: 21666281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.